Literature DB >> 6546829

[Recurrence of duodenal ulcer after therapy with Sucralfat or cimetidine].

E Hentschel, K Schütze, W Dufek.   

Abstract

Relapse rates of duodenal ulcer after treatment with sucralfate or cimetidine were investigated in a one-year follow-up study. During this period 23 out of 27 patients (85.1%) initially treated with sucralfate relapsed, in comparison with 17 out of 21 patients (80.9%) after cimetidine therapy. Recurrence after cimetidine was more often asymptomatic than after sucralfate. These results suggest that recurrence rates of duodenal ulcer are not essentially influenced by the mode of action of the initially used drug. Cytoprotection by sucralfate did not result in fewer or later relapses than reduction of acidity by cimetidine.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6546829

Source DB:  PubMed          Journal:  Wien Klin Wochenschr        ISSN: 0043-5325            Impact factor:   1.704


  4 in total

Review 1.  Gastric cytoprotection. What does it really mean for the prescriber?

Authors:  M Guslandi
Journal:  Drugs       Date:  1991-04       Impact factor: 9.546

2.  Dopamine agonists prevent duodenal ulcer relapse. A comparative study with famotidine and cimetidine.

Authors:  P Sikiric; I Rotkvic; S Mise; M Petek; R Rucman; S Seiwerth; V Zjacic-Rotkvic; M Duvnjak; V Jagic; E Suchanek
Journal:  Dig Dis Sci       Date:  1991-07       Impact factor: 3.199

3.  The refractory ulcer.

Authors:  D W Piper
Journal:  World J Surg       Date:  1987-06       Impact factor: 3.352

Review 4.  Influence of ulcer healing agents on ulcer relapse after discontinuation of acute treatment: a pooled estimate of controlled clinical trials.

Authors:  G Dobrilla; P Vallaperta; S Amplatz
Journal:  Gut       Date:  1988-02       Impact factor: 23.059

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.